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In regenerative medicine approaches involving cell therapy, selection of the appropriate cell type is important in
that the cells must directly (differentiation) or indirectly (trophic effects) participate in the regenerative response.
Regardless of the mode of action of the cells, angiogenesis underlies the success of these approaches. Stem cells
derived from tooth tissues, specifically the periodontal ligament of teeth (periodontal ligament stem cells
[PDLSCs]), have recently been identified as a good source of multipotent cells for cell therapies. PDLSCs have
demonstrated properties similar to mesenchymal stem cells (MSCs), yet, unlike MSCs, their vascular potential
has not been previously demonstrated. Thus, the aim of this study was to determine if PDLSCs could modulate
angiogenesis. In comparison to MSCs and stem cells derived from tooth pulp tissues (SHEDs), we first deter-
mined if PDLSCs released soluble proangiogenic factors with the capacity to induce vessel formation by en-
dothelial cells (ECs). Next, the ability of PDLSCs to modulate angiogenesis was examined through their
cotransplantation with ECs in subcutaneous sites of immunocompromised mice. Finally, the stability of the
PDLSC-mediated vasculature was determined through evaluation of the maturity and functionality of the
vessels formed following PDLSC transplantation. It was determined that PDLSCs produced appreciable levels of
vascular endothelial growth factor and basic fibroblast growth factor-2, and additionally, were able to initiate
in vitro angiogenesis of ECs comparable to MSC- and SHED-mediated angiogenesis. In vivo cotransplantation of
ECs with PDLSCs significantly ( > 50% increase) enhanced the number of blood vessels formed relative to
transplantation of ECs alone. Finally, vessels formed following PDLSC cotransplantation were more mature and
less permeable than those formed after transplantation of EC alone. These data demonstrate for the first time that
PDLSCs have vascular potential, which could make them a very attractive cell population for utilization in
regenerative cell therapies.
Introduction
It has been well established that the ability of a tissue toregenerate is dependent upon the nutrient support sup-
plied by the local vasculature of the site.1,2 The developing
vascular network of a regenerating site is typically depen-
dent upon resident cells within the local microenvironment;
however, because regeneration depends upon the new vas-
culature, strategies aimed to bolster the angiogenic process
have become a focus of tissue engineering and regenerative
therapies.2–4 One approach to enhancing angiogenesis in-
volves cell transplantation, whereby delivery of different
stem and vascular progenitor cells can serve to enhance an-
giogenesis directly (via differentiation into capillaries) or
indirectly (through trophic effects on host vascular cells).5–7
Yet, a limiting factor in cell transplantation strategies is the
identification of a readily available source of cells.
It has been demonstrated that mesenchymal stem cells
(MSCs) derived from bone marrow have angiogenic prop-
erties and the ability to support angiogenesis when used
clinically and in various preclinical model systems. How-
ever, because their procurement requires an invasive bone
marrow aspiration procedure, the emergence of alternative
sources of MSCs offers a less invasive and more user-friendly
approach for the isolation of these cells. Recently, multi-
potent stem cells derived from internal (dental pulp stem
cells [SHEDs]) and external (periodontal ligament stem cells
[PDLSCs]) tooth tissues of extracted teeth have been shown
to express phenotypes of osteoblasts, chondrocytes, adipo-
cytes, fibroblasts, and neuronal cell types.8–10 Although there
is evidence demonstrating that SHEDs, derived from within
the highly vascular dental pulp of teeth, can differentiate into
the functional endothelium,11,12 there is currently no evi-
dence that PDLSCs, derived from the outer periodontal lig-
ament of teeth, can support angiogenesis. Thus, it would be
of great interest to determine whether or not PDLSCs have
angiogenic potential, specifically, the ability to support the
establishment of a functional vasculature.
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Our group has developed and utilized different three-
dimensional (3D) culture and in vivo systems for evaluating
the ability of different interstitial cell types, such as MSCs, to
establish and support angiogenesis. PDLSCs have been im-
plicated as having phenotypic properties similar to those of
MSCs, yet, the angiogenic potential of these cell populations
has not been examined. Thus, the aim of this study was to
address the hypothesis that PDLSCs have the ability to
support angiogenesis. In this report, we investigated the ef-
fects of PDLSCs on endothelial cells’ (EC) ability to initiate
capillary tube formation in vitro and to establish a function-
ally stable vasculature in vivo.
Methods
Derivation of PDLSCs, SHEDs, and MSCs
PDLSCs were harvested as previously described.9 Briefly,
PDLSCs were scraped from the root surface of a tooth into a
p60 dish containing the alpha-minimum essential medium
(aMEM; Gibco). After collection, the cells were centrifuged at
1600 rpm for 5min at room temperature. The supernatant
was aspirated and the cells were resuspended in a phos-
phate-buffered saline (PBS; Gibco #14190) solution with
4mg/mL Dispase II (Roche #04942078001) and 2mg/mL
collagenase type II (Worthington # LS004196) and incubated
at 37C for 60min. The enzyme solution was inactivated with
5mL of aMEM, 15% fetal bovine serum (FBS), and 100mM
ascorbic acid 2 phosphate (ASAP; Sigma A-8960) and
centrifuged at 1600 rpm for 5min at room temperature. Cells
were resuspeneded in 5mL of aMEM, 15% FBS, and 0.1mM
ASAP and transferred to T-25 flasks. The medium was
changed the next day and then every 2–3 days. SHEDs were
isolated from extracted human teeth,13 as previously de-
scribed, and human MSCs isolated from the iliac crest were
commercially purchased (Lonza).
Flow cytometry and multipotency assay
Flow cytometry was performed to determine the expres-
sion of MSC markers according to the criteria proposed by
the Mesenchymal and Tissue Stem Cell Committee of the
International Society of Cellular Therapy (ISCT): CD45,
CD90, CD73, CD105, CD34, CD19, and CD14.14 PDLSCs
were harvested from T150 flasks, transferred into tubes,
washed with PBS, and then incubated with the CD16/CD32
blocking solution, followed by incubation with specific an-
tibodies conjugated with a fluorochrome (Biolegends). Cells
were washed extensively at each step. Analysis was per-
formed on either a Beckman Coulter MoFlo Astrios or CyAn
flow cytometer and the following list of antibodies includes
PE anti-human CD105 antibody
FITC anti-human CD90 (Thy1) antibody




Multipotency of PDLSC cultures was determined by Al-
cian blue (chondrogenic), Oil Red O (adipogenic), and von
Kossa (osteogenic) staining according to previously de-
scribed methods.14 Briefly, following subculture of cells
at > 90% confluency, cells were induced toward osteogenic,
adipogenic, and chondrogenic fates in the appropriate media
according to previously described methods.15 Before staining,
PDLSCs were cultured for 21 days with the respective in-
duction media being changed every 2–3 days.
Angiogenic cytokine secretion
Overnight conditioned media from PDLSCs, MSCs, and
SHEDs were collected and evaluated for the presence of
vascular endothelial growth factor and basic fibroblast
growth factor-2 (bFGF-2) using ELISAs for these two growth
factors, according to the manufacturer’s instructions (R&D
Systems). Concentrations of growth factor were normalized
to the number of cells.
Three-dimensional microcarrier angiogenesis assay
The angiogenic potential of various interstitial cell types
was assessed using a microcarrier-based angiogenesis assay
as described previously.16 Primary human umbilical vein
ECs were cultured in the Endothelial Growth Medium-2
(Lonza), trypsinized at 90% confluence, and counted. Four
million cells were combined with 10,000 Cytodex 3 micro-
carrier beads (Sigma-Aldrich) in 5mL of EGM-2 and pipetted
into an upright T-25 culture flask. The suspension was cul-
tured for 4 h in a 37C, 5% CO2 incubator and agitated gently
every 30min. After cell attachment, the suspension was re-
moved and an additional 5mL of EGM-2 was added. The
suspension was then pipetted into a fresh T-25 and cultured
in normal cell culture position overnight.
The following day, fibrin gels were prepared. Bovine fi-
brinogen (Sigma-Aldrich) was dissolved in the serum-free
EGM-2 and sterile filtered. Gels were created by combining
2.5mg/mL of fibrinogen solution containing approximately
100 HUVEC-coated microcarriers with bovine thrombin
(Sigma-Aldrich), and pipetting the resulting solution into
wells in a 24-well plate. The beads were allowed to settle for
5min, and then the solution was incubated at 37C for 25min
to finish gelation. During the incubation, PDLSCs, SHEDs,
and MSCs were trypsinized and counted. After gelation was
complete, 25,000 cells of the appropriate type were plated on
top of each gel. Cocultures were incubated in a 37C, 5% CO2
incubator. Media were changed every other day.
In vivo angiogenic potential of PDLSCs
Subcutaneous implantation of PDLSCs. Gelatin scaf-
folds (Gelfoam; Pfizer) containing 1· 106 ECs alone or in
combination with 1 · 106 PDLSCs were implanted into sub-
cutaneous pockets on the dorsal region of 7- to 9-week-old
male severe combined immunodeficient (SCID) mice, as
previously described17 (cb17/SCID) (Taconic Laboratories).
Briefly, a small (about 1.5 cm) longitudinal incision was
made into the skin at the center of a shaved area of the back.
Blunt dissection of subcutaneous fascial tissue was per-
formed to create pockets for implants to be placed and the
incisions were closed with interrupted sutures. At 4 weeks,
animals were sacrificed and implants were analyzed for
blood vessel formation.
Cell transplantation for histological evaluation of angio-
genesis. Implants were retrieved at various time points
and fixed overnight in aqueous buffered zinc formalin
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(Z-Fix; Anatech). Implants were then transferred to 70%
EtOH until they were processed and embedded in paraffin.
Paraffin-embedded matrices were cut into serial sections
(5 mm thick) and placed on glass slides for histological anal-
ysis. Tissue sections were stained with Gill’s 3 hematoxylin
(Sigma-Aldrich) and aqueous eosin Y solution (Sigma-
Aldrich) (H&E) to visualize the overall tissue morphology.
Immunostaining of human-derived blood vessels was per-
formed using an anti-human CD31 antibody (DakoCytoma-
tion), respectively, as described previously.18 Tissue sections
were visualized and photographed with the E-800 light mi-
croscope (Nikon). Five samples from each condition were
analyzed manually and digitally. Blood vessels present in the
implants were analyzed for total number. Blood vessels were
identified in hematoxylin and eosin-stained tissues, at· 200
magnification, by defined lumens and the presence of red
blood cells within their boundaries. Mature vessels were de-
fined as vessels whose diameter was > 20mm.
Cell transplantation for evaluation of vessel permeability
with labeled tracer. For subcutaneous implants involv-
ing fluorescent labeling of dextran molecules, cell mix-
tures consisting of either ECs alone or in combination with
PDLSCs or MSCs were spun down and resuspended in a
FIG. 1. Periodontal liga-
ment stem cells’ (PDLSCs)
stemness. (A) PDLSCs ex-
press mesenchymal stem cell
markers CD90 and CD105
and lack expression of the
hematopoietic stem cell mar-
ker CD45 (bottom panels




differentiation of PDLSCs as
measured by phenotypic ex-
pression of osteogenic miner-
alized matrix (von Kossa),
chondrogenic proteoglycans
(Alcian blue), and adipogenic
lipid vacuoles (Oil Red O);
low magnification images
were taken at 40 · ; high
magnification images are
shown at 200· . Color images
available online at www
.liebertpub.com/tea
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previously prepared fibrinogen solution at a final concen-
tration of 10 million cells/mL. Immediately before injection,
5% FBS and 6 mL of thrombin solution (50U/mL; Sigma-
Aldrich) were added to 300 mL of fibrinogen cell solution.
Solutions were immediately injected subcutaneously on the
dorsal flank of the mouse, with two implants per animal.
Animals were kept stationary for 5min to allow for implant
polymerization, and were then placed in fresh cages for re-
covery. Five replicates were completed for each sample type
(ECs only, EC-BMSCs, EC-PDLSCs).
Implants were retrieved after 7 days following systemic
administration of a fluorescent tracer. Mature capillaries
are impermeable to dextrans over a molecular weight of
65 kDa.19 Therefore, a 70-kDa Texas Red-conjugated dextran
(kex/em of 595/615 nm; Invitrogen) was chosen as a func-
tionally defining tracer as described previously.20,21 This
dextran molecule contains free lysines, which are fixable in 4%
paraformaldehyde (PFA). Before implant retrieval, mice were
placed in a restraint device and 100mL of a 5mg/mL dextran
solution in PBS was then injected through the tail vein. After
injection, mice were placed into fresh cages, and the tracer was
allowed to circulate systemically for 10min. Animals were
then euthanized and implants were surgically excised.
For immunofluorescence, explants were fixed in 4% PFA
for 1 h and then moved to 0.4% PFA overnight. Implants
were rinsed for three washes of 5min each with PBS, pH 7.4,
and incubated in 30% sucrose for 48 h at 4C. Next, implants
were transferred to a solution containing two parts 30% su-
crose and one part optimal cutting temperature (OCT) em-
bedding compound (Andwin Scientific) for 24 h. Each
sample was embedded in 100% OCT in a disposable plastic
mold (Fisher Scientific), and flash-frozen on the surface of
liquid nitrogen. Frozen sections were generated from each
sample by the histology core at the University of Michigan
School of Dentistry. For staining, slides were prewarmed for
20min at 25C and then rinsed with three washes of PBS.
Sections were blocked with 5% goat serum in PBS to elimi-
nate nonspecific protein binding. The primary antibody (ei-
ther anti-rabbit human CD31; Santa Cruz Biotechnologies or
human anti-mouse alpha smooth muscle actin [aSMA]; Ab-
cam) was diluted 1:50 in 5% goat serum and added to
samples for an overnight incubation at 4C. The unbound
antibody was removed at the end of the incubation with
three washes with PBS. The secondary antibody (Alexa
Fluor-488 goat anti-rabbit; Invitrogen) was added to tissues
at a 1:100 dilution and tissues were incubated 30min at room
temperature. The unbound antibody was removed by an
additional three washes with PBS. Slides were then mounted
with VectaShield (Vector Labs) and covered with a #1 glass
coverslip before imaging. Imaging was performed on an
Olympus IX81 microscope with a 100-W high pressure
mercury lamp (Olympus) and a Hammamatsu camera
(Bridgewater). Representative images were chosen for each
condition.
Statistical analysis
Statistical analyses were performed with Instat software
(Graphpad Software). Descriptive analyses were performed
initially, followed by the use of Student’s t-tests. Statistical
significance was measured as p < 0.05. All data are plotted as
mean – SE. Statistically significant differences in histomor-
phometric analysis were determined by using two-tailed




Cell surface marker expression of CD90 and CD105 was
evaluated for PDLSCs in that these markers are all consid-
ered important determinants in defining stemness associ-
ated with MSCs.14 Following isolation and cell expansion,
PDLSCs expressed high levels of CD90 (> 98%), and CD105
(> 85%) and did not express the hematopoietic stem cell
marker CD45 (Fig. 1A). The stemness of PDLSCs was also
confirmed through their capacity to differentiate toward
different cellular lineages following culture under adipo-
genic, chondrogenic, and osteogenic conditions. After 3
weeks of culture, commitment toward different tissue line-
ages was evaluated through lineage-specific staining of in-
duced cells. PDLSCs were stained with Oil Red O, Alcian
blue, and von Kossa. In the uninduced control culture con-
ditions, the Oil Red O, Alcian blue, and von Kossa stainings
were all negative. In adipogenic conditions, Oil Red O
staining was used to detect intracellular lipid-rich vacuoles
and morphological changes in cell shape. The results con-
firmed that cells were differentiated toward an adipogenic
lineage (Fig. 1B). Similarly, in cells grown under chondro-
genic conditions, the presence of chondrogenic proteogly-
cans was indicated by positive Alcian blue staining (Fig. 1B),
confirming chondrogenic differentiation. Under osteogenic
culture conditions, deposition of mineralized matrix indica-
tive of osteoblasts was evident through positive von Kossa
staining (Fig. 1B).
FIG. 2. Angiogenic cytokine production. (A) Twenty-four-
hour vascular endothelial growth factor (VEGF) secretion
from mesenchymal stem cells (MSCs), dental pulp stem cells
(SHEDs), and PDLSCs; (B) 24-h basic fibroblast growth fac-
tor-2 (bFGF-2) secretion from MSCs, SHEDs, and PDLSCs.
*Indicates p< 0.05 (compared to SHEDs).
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Angiogenic growth factor production
PDLSCs were evaluated in their ability to produce the
highly angiogenic cytokine vascular endothelial growth fac-
tor (VEGF), and compared with production from MSCs and
SHEDs, with both of these cell types being known to produce
VEGF.22–25 PDLSCs showed equivalent levels of VEGF pro-
duction to MSCs (Fig. 2A) and significantly ( p< 0.05) higher
levels compared with SHEDs.
PDLSCs were also evaluated for their ability to produce
another proangiogenic cytokine, bFGF. Similar to VEGF
production, bFGF secretion was detected from PDLSCs,
MSCs, and SHEDs (Fig. 2B). All cell types produced signif-
icantly lower concentrations of bFGF than VEGF, yet dif-
ferences between the cell types were not statistically
significant.
PDLSCs support EC vessel formation
ECs were grown on microbeads placed in a 3D gel
through which different angiogenic stimuli can induce EC
differentiation and formation of capillary vessels. With this
system, our group has previously demonstrated that inter-
stitial cells such as MSCs have the ability to support EC
differentiation into capillary tubes.26 Figure 3A shows vessel
migration from microbeads under conditions where
PDLSCs, MSCs, and SHEDs were cocultured in the 3D gel.
Compared with when no supporting cells are present in the
FIG. 3. PDLSCs stimulate endothelial cell (EC) vessel formation. (A) Photomicrographs (10 ·magnification) of EC-coated
microbeads placed within fibrin gels containing MSCs, PDLSCs, SHEDs, or no cells. Images show differentiating ECs forming
vessels elongating from microbeads. (B) Quantification of the number of vessels formed by ECs when cultured in the
presence of MSCs, PDLSCs, SHEDs, or no other interstitial cell type. (C) High magnification (20· ) images of vessels
highlighting branching of tubular networks forming from ECs on microbeads. (D) Quantification of the total vessel network
length of tubular networks formed by ECs when cultured in the presence of MSCs, PDLSCs, SHEDs, or no other interstitial
cell type. *Indicates p< 0.05 (compared to MSCs, PDLSCs, and SHEDs).
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coculture, PDLSCs clearly supported EC vessel formation
comparable to that seen with MSCs. SHEDs also supported
angiogenesis to the same degree as MSCs. The total number of
vessels formed in these conditions was quantified and dem-
onstrated that PDLSCs were able to induce an equivalent
number of vessels than those produced by MSCs and SHEDs
(Fig. 3B). In addition to evaluating the number of vessels
formed, an evaluation of the robustness of the angiogenic re-
sponse was evaluated by determining the total network length
of vessels formed in response to PDLSCs. In higher magnifi-
cation, it was clear that MSCs, PDLSCs, and SHEDs were able
to induce vessel structures that had branching and luminal
morphologies indicative of EC capillary formation (Fig. 3C).
Quantitatively, the total network length of vessels formed from
ECs was the same between conditions containing cocultured
MSCs, PDLSCs, and SHEDs (Fig. 3D). Again, EC cultured
alone were not able to illicit this angiogenic response.
In vivo angiogenic potential of PDLSCs
Histological analysis. Four weeks after subcutaneous
implantation of ECs, and ECs in combination with PDLSCs,
implants were harvested and evaluated for neovasculariza-
tion within the scaffolds. In evaluation of total blood vessel
formation between ECs and ECs cotransplanted with
PDLSCs, PDLSCs appeared to form more vessels throughout
the implant (Fig. 4A). In evaluation of the maturity of the
vessels between the two conditions, there appeared to be a
greater number of larger, more mature vessels in the condi-
tion where the PDLSCs were cotransplanted. Of the vessels
formed, we also wanted to determine the percentage of
vessels that were of human origin (derived from trans-
planted cells) and thus sections were immunostained for
detection of human CD31 antigen (Fig. 4B). Images clearly
showed vessels in both groups derived from human cells and
chimeric vessels derived from both human and host mouse
cells. Quantitative analysis confirmed that there was a sta-
tistically significant increase in the number of total vessels
formed and in the number of mature vessels formed when
ECs were cotransplanted with PDLSCs (Fig. 4C). In the EC
condition, 67% of the vessels were human derived or chi-
meric vessels from human and host origin. In the condition
with PDLSCs, although 86% of the cells were human de-
rived, this difference was not statistically significant.
FIG. 4. PDLSC effect on in vivo
angiogenesis. (A) Photo-
micrographs of histological sections
(H&E stained) of subcutaneous im-
plants containing ECs alone or
ECs +PDLSCs (arrows point to
blood vessels). (B) Photo-
micrographs of histological sections
immunostained for human CD31 to
identify blood vessels (arrows)
formed from implanted human
cells (ECs or PDLSCs). Quantifica-
tion of (C) total vessels, human-
derived vessels, and mature (diam-
eter > 20 mm) vessels between con-
ditions. Values represent mean – SE
(n = 5). *p< 0.05. Color images
available online at www
.liebertpub.com/tea
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Vessel permeability. Evaluation of vessel maturation
was further examined in another mouse model through the
use of fluorescent labeling of vessels and their ability to
maintain fluorescently labeled dextran molecules following
their injection. In this model, we have previously demon-
strated that MSC cotransplantation with ECs yields less
permeable and more mature vessels than those formed from
EC transplantation alone.20,21 In the present study, fluores-
cent staining showed more dextran contained within the
vessels where either MSCs or PDLSCs were cotransplanted,
relative to the condition where only ECs were tranplanted
(Fig. 5A). Again, the appearance of vessels formed in these
conditions, relative to transplantation of ECs alone, was that
of larger, more mature vessels, characteristic of vessels that
are associated with pericytes. Immunostaining for pericytes
with aSMA demonstrated that transplanted PDLSCs were
widely dispersed around vessels (Fig. 5B), confirming their
pericytic role in the development of a de novo, functional
vasculature.
Discussion
Cell transplantation approaches in regenerative medicine
rely heavily upon the establishment of a supporting vascu-
lature to sustain tissue regeneration. In this report, we ex-
amined the angiogenic properties of PDLSCs in vitro and
in vivo. PDLSCs secrete angiogenic cytokines and in a 3D
culture system and demonstrated the ability to induce EC
vessel formation through secretion of soluble factors. Ad-
ditionally, when cotransplanted with ECs, PDLSCs signifi-
cantly enhanced angiogenesis and even further, produced
vessels that were larger and functionally more mature than
those formed following transplantation of ECs alone.
It has been previously demonstrated that MSCs produce
angiogenic factors, which can support the development of a
functional vasculature and a number of studies have impli-
cated VEGF as being a major mediator of this response.22,27,28
Oral-derived stem cells exhibit similar genotypic and phe-
notypic expression profiles to MSCs and the production of
FIG. 5. PDLSC effect on
functional vessel formation.
(A) Red fluorescent 70 kDa
dextran was administered
systemically to mice before
implant removal on day 7.
Following fixation and cryo-
sectioning, tissues were
stained for human CD31
(green) and imaged. Stromal
cell identity appeared to
modulate the retention of
dextran within the vessel lu-
men, which indirectly sug-
gests variable maturity of the
vessels across conditions.
Implants contain ECs only,
EC +MSCs, or ECs +PDLSCs.
Images are 10 ·magnifica-
tion; scale bar= 100mm and
40·magnification of the same
region; scale bar= 20mm.
(B) Cryosections from day 7
containing red dextran were
stained for human alpha
smooth muscle actin (aSMA,
green) and imaged at
10 ·magnification. Implants
contain ECs only, ECs +
MSCs, or ECs +PDLSCs.
Color images available online
at www.liebertpub.com/tea
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VEGF from PDLSCs validates yet another parallel between
these cell types. Both SHEDs and PDLSCs are anatomically
found in highly vascular regions, located in close proximity
to blood vessels within the tooth (SHEDs) and surrounding
the tooth (PDLSCs). It is thus not surprising that they have
the capacity to produce factors that could initiate or sustain
an angiogenic response, as this could be a physiological
mechanism used when needed in response to changes in the
local microenvironment (i.e., injury).
In demonstrating that PDLSCs produced proangiogenic
cytokines VEGF and b-FGF, we wanted to determine whe-
ther or not soluble secretion of angiogenic factors played a
role in the initiation of angiogenesis. Studies from our group
and others have previously demonstrated that this model
can be used to examine the effects of soluble signals on the
EC’s ability to form 3D vessel networks.29,30 Cells that have
been implicated as pericytes or supporting cells show the
capacity to induce EC vessel formation when cocultured in
this system, without direct cell–cell contact. In this system,
ECs will not spontaneously form elongated tubes and
branches without coculture using an angiogenic supporting
cell type. When we cultured both MSCs and PDLSCs, strik-
ing similarities were observed in the vessels and branching
networks seen not only between these two cell types, but also
in comparison to SHEDs. From a therapeutic standpoint,
these findings are significant in that they provide evidence
that PDLSCs have the capacity to elicit an angiogenic re-
sponse, which could facilitate regeneration, regardless of the
tissue of interest. There is evidence that ECs induce osteo-
genic and odontogenic induction of PDLSCs,31,32 yet, our
study is the first report demonstrating a reciprocal relation-
ship of the PDLSCs on ECs. The production of VEGF most
likely contributes to this response, however, our study was
not designed to address to what extent VEGF plays a role.
It was clear from the in vitro studies that PDLSCs had
angiogenic properties, yet, we wanted to determine whether
the vascular potential of these cells had an effect on a func-
tional vasculature. Thus, PDLSCs were subcutaneously co-
transplanted with ECs in an in vivo model of angiogenesis
and although there was no difference in the number of hu-
man-derived vessels formed between implants with ECs and
implants with ECs cotransplanted with PDLSCs, there was
an overall net increase in the number of vessels formed.
These data are consistent with other reports of enhanced
wound healing models of MSC cotransplantation with ECs
or ECs progenitors, yet, no other reports have investigated
the effects of PDLSCs on angiogenesis when cotransplanted
with ECs. In that there was no net increase in human-derived
vessels between conditions, the data suggest that the trans-
planted PDLSCs did not contribute directly to the formation
of vessels through their own differentiation into ECs, but
instead may have been able to bolster the host angiogenic
response. Again, lending to the similarity of their properties
with MSCs, these data are in alignment with MSCs’ ability to
bolster angiogenesis in many different model systems of
wound healing involving bone, cardiac, and cerebral tissue
repair. Another possible function of transplanted oral-
derived stem cells could be in their capacity to serve as EC
supporting cells or pericytes. It has been recently reported
that after isolation and expansion in culture, PDLSCs ex-
press cell surface markers associated with pericytes.33 In our
in vivo model, aSMA staining confirmed the presence of
pericytes in the condition where PDLSCs were cotrans-
planted with ECs. This role as a supporting pericyte is also
supported by the observation that in the condition in which
PDLSCs were transplanted, there were a greater number of
larger, more mature vessels, relative to when only ECs were
transplanted. Additionally, it appeared that these vessels
were more functional in that they were able to maintain the
dextran tracer within the lumens of the vessels to a greater
extent than those in the implants where only ECs were
transplanted.
Taken together, the findings of this investigation highlight
the angiogenic potential of PDLSCs. This cell population
demonstrated the capacity to stimulate EC differentiation
into vessels through soluble signaling, and to support an-
giogenesis in vivo. Because these cells are derived from nor-
mally discarded tissues (i.e., extracted teeth), they could
serve functional roles in cell therapy applications aimed not
only to regenerate tissues, but also to enhance angiogenesis.
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